Sarah Cannon, Genospace Announce Merger
Complete the form below to unlock access to ALL audio articles.
Sarah Cannon has announced that Genospace will merge with its organization and become a wholly-owned subsidiary. By joining forces, Sarah Cannon and Genospace will harness and use molecular profiling data to more effectively match cancer patients to cutting-edge therapies in clinical trials.
Genospace, which will remain based in Cambridge, Mass., is leading the development and enhancement of a cloud-based system that enables analysis of disparate data from clinical and laboratory sources across patient populations.
“Genospace’s innovative technology approach to understanding each patient’s cancer directly supports our strategic goal of personalizing care delivery, “said Jonathan B. Perlin, MD, PhD, MSHA, MACP, FACMI, President, Clinical Services and Chief Medical Officer at Hospital Corporation of America (HCA). “By tailoring treatments based on the unique genetic make-up of a patient’s cancer, we can more effectively treat the disease.”
Through the collaboration of Sarah Cannon and Genospace, the genomics data technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.
“As genomic information advances, it is crucial that oncologists and researchers have rapid access to an efficient and nimble technology solution for interpreting molecular data and guiding clinical decision making,” said Howard A. “Skip” Burris III, MD, President, Clinical Operations and Chief Medical Officer, Sarah Cannon. “Genospace’s leadership in this field will help us to transform the way we gather and analyze genomic information, resulting in better identification of effective treatment options for our patients.”
The company’s platform also provides patient-facing portals and disease-specific communities to support and educate patients across disease sites throughout the cancer journey.
“Genospace and Sarah Cannon share an unwavering commitment to serve people facing cancer by developing innovative approaches to treating their disease to ultimately improve outcomes,” said Mick Correll, CEO at Genospace. “Bringing together the expertise of Sarah Cannon’s physicians coupled with our leadership in molecular data integration and interpretation, we can impact the lives of hundreds of thousands of patients. We look forward to this next chapter at Genospace and to the advancements that will be made through our collaborative efforts.”
This article has been republished from materials provided by Sarah Cannon Cancer Institute. Note: material may have been edited for length and content. For further information, please contact the cited source.
